Can tumor-antigen anchoring help concentrate death-receptor activation where FOLR1 is expressed?
The BaCa design combines FOLR1 recognition with DR5 engagement in one antibody construct. In preclinical ovarian cancer systems, the study tested whether FOLR1 anchoring can help position DR5 agonism at tumor cells. The related invention belongs to a patent family that includes a U.S. grant in 2026.
FOLR1 is expressed in many ovarian tumor settings. DR5 is a receptor capable of initiating apoptosis when properly activated. The design uses dual specificity to connect tumor recognition to death-receptor signaling.
Figures in the original paper
Figure 1 — BaCa formats, binding and cell-viability assays (external link) · Figure 6 — Preclinical tumor-model activity (external link)
Evidence and methods
The authors engineered and compared dual-specificity antibody formats, measured target binding and death signaling, and studied ovarian tumor models. The paper includes cell-based experiments and in vivo preclinical work; it does not describe an approved human therapy.
One construct recognizes two targets
The article describes antibody architecture combining FOLR1 and DR5 specificity.
Anchoring changes response context
The reported experiments test FOLR1-dependent localization of DR5 agonism in ovarian cancer systems.
Preclinical antitumor activity
The paper reports cell and model-system effects that support further investigation of the format.
Inside the study
One molecule, two jobs
The BaCa construct uses FOLR1 recognition to anchor a DR5-directed death signal at cells with that tumor-associated antigen. The design addresses the problem that binding a death receptor alone may not create productive receptor clustering.
Evidence sequence
The article proceeds from antibody architecture and binding to cell-death assays and mouse tumor experiments. Each stage answers a narrower question than patient efficacy.
Patent relationship
The later U.S. grant and its earlier published application document the same invention family. A patent grant establishes legal claims, not regulatory approval or clinical activity.
Interpretation
FOLR1 binding supplies a tumor-associated anchor, while DR5 binding is intended to promote receptor clustering and apoptosis. The design rationale and observed preclinical responses are separate from clinical validation.
Evidence stage
Proof of concept in laboratory and animal-model settings. The antibody is not represented here as an approved treatment. The U.S. grant and earlier application are members of one family, not separate inventions.